Sidgiddi, S.; Ranganathan, U.; Gautam, A. DFD-03 (0.1% Tazarotene), Twice-Daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product With Once-Daily Overnight Application. J of Skin 2017, 1, s46.